<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221230056987N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-09</date_registration>
      <primary_sponsor>Birjand University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the relation between prophylactic antibiotics and prevalence of surgical site infection in elective laparoscopic cholecystectomy in low-risk patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the relation between prophylactic antibiotics and prevalence of surgical site infection in elective laparoscopic cholecystectomy in low-risk patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>122</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69377</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Intervention and Observation groups (A and B respectively) will be randomized in a block-to-block fashion, In which four block of 4 (AABB) is designed and randomly put after another until the designated sample size is reached. the aforementioned pattern will be used to distribute patients into a respected group, Blinding description: This study will be a double-blinded intervention so that the patient and the surgical team (residents and attending in charge of the patient) will not know about the allocation of the groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Symptomatic Cholelithiasis. Condition 2: Gallbladder Polyp. Condition 3: Chronic Cholecyctitis. Condition 4: Gallstone pancreatitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in this group will receive prophylaxis in the form of one gram of intravenous cefazolin before surgical incision. All patients will be subjected to classic laparoscopic cholecystectomy in the 4-port method under direct supervision or by the university attendant at the educational center of Imam Reza Hospital. The preparation of the operation site will be performed according to the instructions of the operating room of Imam Reza (AS) hospital and with 10% iodine solution. Gallbladder will be removed directly without using endobag through epigastric port. The duration of the operation, the opening of the gallbladder or bleeding from the bed and the insertion of the catheter during the operation will be recorded for each patient. After the operation, the patients will be discharged with or without a drain and according to the opinion of the concerned doctor, until the significant recovery of pain and diet tolerance, and if there is no fever and the wound is clean. Intervention 2: Control group: patients in this group will not receive antibiotics before surgery and will instead receive a serum that does not contain antibiotics (placebo). All patients will be subjected to classic laparoscopic cholecystectomy in the 4-port method under direct supervision or by the university attendant at the educational center of Imam Reza Hospital. The preparation of the operation site will be performed according to the instructions of the operating room of Imam Reza (AS) hospital and with 10% iodine solution. Gallbladder will be removed directly without using endobag through epigastric port. The duration of the operation, the opening of the gallbladder or bleeding from the bed and the insertion of the catheter during the operation will be recorded for each patient. After the operation, the patients will be discharged with or without a drain and according to the opinion of the concerned doctor, until the significant recovery of pain and diet tolerance, and if there is no fever and the wound is clean.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be made available in the form of SPSS files upon request

When:
The access period starts after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
Overall evaluation of the research, re-analysis of the data, use of the data for further studies

Where to obtain:
Electronic correspondence with the researcher, Dr. Ali Najafi Semnani, through the following email address

Sirius.ali@gmailcom

How to obtain:
Sending an email to the address provided and receive a response within 5 working days

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Nadjafi-Semnani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>East Saidi St., No. 14, Unit 8</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9713664679</zip>
        <telephone>+98 56 3222 9129</telephone>
        <email>Sirius.ali@gmail.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Nadjafi-Semnani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>East Saidi St., No. 14, Unit 8</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9713664679</zip>
        <telephone>+98 56 3222 9129</telephone>
        <email>Sirius.ali@gmail.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Symptomatic Cholelithiasis
Gallbladder polyps
Chronic cholecystitis
Hx of Biliary Pancreatitis</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Breast Feeding mothers
Allergy to Cephalosporins
Hx of Chemotherapy
Hx of CKD or Chronic Liver Diseases
Diabetes
Regular Steroid Consumption
Acute Cholecyctitis
Hx of Antibiotic consumption 5 days prior to intervention</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K80</hc_code>
      <hc_code>K87</hc_code>
      <hc_code>K80.10</hc_code>
      <hc_code>K85.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cholelithiasis</hc_keyword>
      <hc_keyword>Disorders of gallbladder, biliary tract and pancreas in diseases classified elsewhere</hc_keyword>
      <hc_keyword>Calculus of gallbladder with chronic cholecystitis without obstruction</hc_keyword>
      <hc_keyword>Biliary acute pancreatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in this group will receive prophylaxis in the form of one gram of intravenous cefazolin before surgical incision. All patients will be subjected to classic laparoscopic cholecystectomy in the 4-port method under direct supervision or by the university attendant at the educational center of Imam Reza Hospital. The preparation of the operation site will be performed according to the instructions of the operating room of Imam Reza (AS) hospital and with 10% iodine solution. Gallbladder will be removed directly without using endobag through epigastric port. The duration of the operation, the opening of the gallbladder or bleeding from the bed and the insertion of the catheter during the operation will be recorded for each patient. After the operation, the patients will be discharged with or without a drain and according to the opinion of the concerned doctor, until the significant recovery of pain and diet tolerance, and if there is no fever and the wound is clean.</i_keyword>
      <i_keyword>Control group: patients in this group will not receive antibiotics before surgery and will instead receive a serum that does not contain antibiotics (placebo). All patients will be subjected to classic laparoscopic cholecystectomy in the 4-port method under direct supervision or by the university attendant at the educational center of Imam Reza Hospital. The preparation of the operation site will be performed according to the instructions of the operating room of Imam Reza (AS) hospital and with 10% iodine solution. Gallbladder will be removed directly without using endobag through epigastric port. The duration of the operation, the opening of the gallbladder or bleeding from the bed and the insertion of the catheter during the operation will be recorded for each patient. After the operation, the patients will be discharged with or without a drain and according to the opinion of the concerned doctor, until the significant recovery of pain and diet tolerance, and if there is no fever and the wound is clean.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Surgical site infection, superficial*. Timepoint: 7 days after the operation. Method of measurement: Diagnosis of superficial surgical site infection according to the physician's opinion and based on clinical or paraclinical findings.</prim_outcome>
      <prim_outcome>Surgical site infection, deep*. Timepoint: 7 days after the operation. Method of measurement: Diagnosis of deep surgical site infection according to the physician's opinion and based on clinical or paraclinical findings.</prim_outcome>
      <prim_outcome>Surgical site infection, Intra abdominal*. Timepoint: 7 days after the operation. Method of measurement: Diagnosis of intra abdominal surgical site infection according to the physician's opinion and based on clinical or paraclinical findings.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Birjand University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-06</approval_date>
        <contact_name>Ethics committee of Birjand University of Medical Sciences</contact_name>
        <contact_address>Birjand University of Medical Sciences, Ghafari Street, Birjand, South Khorasan, Iran Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
